Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial

Summary In postmenopausal women with low bone mass and hormone-receptor-positive breast cancer on an aromatase inhibitor, risedronate maintained skeletal health assessed by bone density and turnover markers. Women with the greatest decreases in bone turnover markers at 12 months had the greatest inc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Osteoporosis international 2015-06, Vol.26 (6), p.1857-1864
Hauptverfasser:	Greenspan, S. L., Vujevich, K. T., Brufsky, A., Lembersky, B. C., van Londen, G. J., Jankowitz, R. C., Puhalla, S. L., Rastogi, P., Perera, S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic Agents, Hormonal - adverse effects Antineoplastic Agents, Hormonal - therapeutic use Aromatase Inhibitors - adverse effects Aromatase Inhibitors - therapeutic use Biomarkers - blood Bone density Bone Density - drug effects Bone Density Conservation Agents - adverse effects Bone Density Conservation Agents - therapeutic use Bone Remodeling - drug effects Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - physiopathology Double-Blind Method Drug therapy Endocrine therapy Endocrinology Female Humans Medicine Medicine & Public Health Middle Aged Original Article Orthopedics Osteoporosis, Postmenopausal - chemically induced Osteoporosis, Postmenopausal - physiopathology Osteoporosis, Postmenopausal - prevention & control Rheumatology Risedronic Acid - adverse effects Risedronic Acid - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!